Cadisegliatin has the potential to be the first oral adjunct therapy for type 1 diabetes CATT1 Phase 3 trial expected to ...
Hybrid closed-loop insulin delivery lowers risk for hypoglycemic coma and increases rate of ketoacidosis for young people with T1D.
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced its revolutionary Omnipod 5 ...
19h
Verywell Health on MSNWhat Happens When You Take Growth Hormone Injections?Growth hormone injections deliver a synthetic growth hormone to the body to treat hormone deficiencies and other health ...
Cadisegliatin has the potential to be the first oral adjunct therapy for type 1 diabetes CATT1 Phase 3 trial expected to resume following submission of protocol amendment shortening the overall durati ...
Tv Therapeutics' Phase 3 trial for cadisegliatin in type 1 diabetes resumes after FDA lifts hold, with a revised six-month ...
Apollo Health, a leading provider of clinically proven innovative health solutions for cognition, has partnered with Trifecta Nutrition, the nation's largest science-backed meal delivery service ...
Announced positive preliminary 12-week clinical results, building on already released 4-week results, of ongoing type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplan ...
Insulet shows bullish trends with strong growth, favorable Wall Street ratings, and a 3.2:1 reward-risk ratio. Read more on ...
Family history increases diabetes risk, but these proven strategies can help you overcome genetic predisposition and prevent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results